Premium
Targeting MYC in cancer therapy: RNA processing offers new opportunities
Author(s) -
Koh Cheryl M.,
Sabò Arianna,
Guccione Ernesto
Publication year - 2016
Publication title -
bioessays
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.175
H-Index - 184
eISSN - 1521-1878
pISSN - 0265-9247
DOI - 10.1002/bies.201500134
Subject(s) - rna splicing , messenger rna , rna , transcription (linguistics) , biology , rna polymerase ii , cancer research , translation (biology) , alternative splicing , computational biology , microbiology and biotechnology , gene expression , gene , genetics , promoter , linguistics , philosophy
MYC is a transcription factor, which not only directly modulates multiple aspects of transcription and co‐transcriptional processing (e.g. RNA‐Polymerase II initiation, elongation, and mRNA capping), but also indirectly influences several steps of RNA metabolism, including both constitutive and alternative splicing, mRNA stability, and translation efficiency. As MYC is an oncoprotein whose expression is deregulated in multiple human cancers, identifying its critical downstream activities in tumors is of key importance for designing effective therapeutic strategies. With this knowledge and recent technological advances, we now have multiple angles to reach the goal of targeting MYC in tumors, ranging from the direct reduction of MYC levels, to the dampening of selected house‐keeping functions in MYC‐overexpressing cells, to more targeted approaches based on MYC‐induced secondary effects.